CME Accreditation for Gaucher Disease
Lysosomal Storage Diseases: Central Symptoms and Comorbidities
Start date: February 1 2022
End date: February 1, 2023
Estimated time to complete: 1 hour
Activity Description
This CME activity highlights how symptoms and comorbidities involving the central nervous system have a key role in how physicians manage patients with lysosomal storage disorders. Key medical problems discussed include cognitive deterioration, behavioral disorders, ophthalmologic problems, neuromuscular deterioration, Parkinson’s disease, depression, and seizures. Newer therapies that allow treatment to cross the blood brain border are also discussed.
Activity Faculty
Ozlem Goker-Alpan, MD
Founder and President
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Swati Sathe, MD
Medical Director
CHDI Management
Associate Professor (Voluntary), Rutgers NJMS
Target Audience
This activity provides continuing education credit for Physicians, Physician Assistants, Nurses, Nurse Practitioners, Genetic Counselors as well as a statement of participation for other attendees.
Learning Objectives
At the end of this activity, participants should be able to:
- Describe the spectrum of neurological involvement in LSDs
- Describe the pathophysiology of CNS involvement in LSDs
- Review current therapies and how they help neurological involvement in LSDs
- Describe how newer treatment may impact neurological symptoms in certain LSDs
AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™ for Physicians, PA’s, NP’s and Genetic Counselors (category 2 CEU’s). This activity provides a maximum of 1 hours of continuing nursing education credit. All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Clinical Diversity and Genetic Variation in Lysosomal Disorders
Start date: July 16, 2021
End date: July 15, 2022
Estimated time to complete: 2 hours
Activity Description
Drs. Ozlem Goker-Alpan, Gregory Grabowski and Soumeya Bekri provide a thorough description of the clinical diversity and genetic variations that can help guide personalized therapies. The session includes a Q&A section at the end hosted by Dr. Uma Ramaswami.
Activity Faculty
Ozlem Goker-Alpan, MD
Founder and President
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
Gregory Grabowski, MD
Department of Pediatrics
University of Cincinnati College of Medicine
Division of Human Genetics
Soumeya Bekri, MD, PhD
Rouen University Hospital, France
Target Audience
This activity provides continuing education credit for Physicians, Physician Assistants, Nurses, Nurse Practitioners, Genetic Counselors as well as a statement of participation for other attendees.
Learning Objectives
At the end of this activity, participants should be able to:
- Explain the principles of Pathogenic Processes in LSDs.
- Explain that lysosomal composition, shape, contents, numbers differ between cell types
and have an effect on disease expression. - Review the evolving understanding of lysosomal autophagy functions.
AffinityCE designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™ for Physicians, PA’s, NP’s and Genetic Counselors. This activity provides a maximum of 2 hours of continuing nursing education credit. All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Novel Technologies and Emerging Therapies for Precision Medicine
Start date: July 16, 2021
End date: July 15, 2022
Estimated time to complete: 1.5 hours
Activity Description
Drs. Shoshana Revel-Vilk and Neil Weinreb discuss the latest digital and pharmaceutical advances that are advancing how we manage persons with lysosomal storage disorders, including Gaucher disease. The session includes a Q&A section at the end hosted by Dr. Ozlem Goker-Alpan.
Activity Faculty
Shoshana Revel-Vilk, MD, PhD
Shaare Zedek Medical Center, Israel
Neil Joseph Weinreb, MD
University of Miami, FL, USA
Learning Objectives
At the end of this activity, participants should be able to:
- Detail the different technologies used in digital health.
- Discuss the benefits and challenges of the different technologies of digital health.
- Explain projects of digital health in Gaucher disease.
- Identify some of the different clinical manifestations of representative lysosomal
storage disorders (LSDs) and how persistent unmet needs for treatment are driving the
search for innovative small molecule treatments. - Identify the increasing numbers of non-chaperone small molecule oral therapies as
alternative treatments for disorders currently treated with intravenous ERTs and as novel treatments for diseases in which ERT is either insufficient or inapplicable.
AffinityCE designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™ for Physicians, PA’s, NP’s and Genetic Counsleors. This activity provides a maximum of 1.5 hours of continuing nursing education credit. All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Gaucher Disease Research Highlights: ASH 2020
Start date: March 31, 2021
End date: March 31, 2022
Estimated time to complete: 0.25 hours
Activity Description
At the American Society of Hematology Annual Meeting (ASH 2020), new information and data were presented on Gaucher disease, a rare lysosomal storage disorder, that requires a team of health care professionals to properly manage. This CME activity highlights the latest information about Gaucher disease from ASH 2020 and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare condition.
Activity Faculty
Derralynn Hughes, MD, DPhil, FDCP, FRCPath
Professor of Experimental Haematology
University College London
Clinical Director of Research and Innovation
Royal Free London NHS Foundation Trust
United Kingdom
Target Audience
This activity has been designed to meet the educational needs of physicians caring for individuals with Gaucher disease. Other members of the care team may also participate.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage people with Gaucher disease and its clinical relevance.
American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™.
Physicians interested in learning more about Gaucher disease as well as other rare lysosomal storage disorders, are encouraged to explore available CME courses offered through CheckRare. Educational modules below are highly informative but the CME availability has expired.
Additional Educational Modules
CME IS NO LONGER AVAILABLE FOR THESE MODULES:
Gaucher Disease Research Highlights
Release date: 04/30/20
Expiration date: 04/30/21
Estimated time to complete: 0.25 hours
Activity Description
At WORLDSymposium 2020, new information and data were presented on Gaucher disease, a rare lysosomal storage disorder. This CME/CNE activity highlights the latest information about Gaucher disease from WORLDSymposium and provides expert analysis of its clinical relevance for busy members of the care team in order to help them care for patients with this rare disease.
Activity Faculty
Neal Weinreb, MD, FACP
Regional Coordinator and Chair of the International Collaborative Gaucher Group
University of Miami UHealth Sylvester Cancer Center Coral Springs
Coral Springs, FL
Target Audience
This activity has been designed to meet the educational needs of physicians, nursing professionals and other members of the team caring for patients with Gaucher disease.
Learning Objective
After participating in the activity, learners should be better able to:
- Describe the latest research being presented to better manage Gaucher disease and its clinical relevance
Gaucher Disease: Diagnosis & Management
Module 1: Gaucher Disease: Epidemiology and Pathophysiology
Learning Objective
After participating in the activity, learners should be better able to:
- Describe the clinical picture of Gaucher disease
Module 2: Signs and Symptoms of Gaucher Disease
Learning Objective
After participating in the activity, learners should be better able to:
- Identify the signs and symptoms a person might present with that would lead to a diagnosis of Gaucher Disease
Module 3: Overcoming Diagnostic Challenges in Gaucher Disease
Learning Objective
After participating in the activity, learners should be better able to:
- Identify strategies for overcoming challenges to diagnosing Gaucher disease
Module 4: Exploring Management Strategies for Type 1 Gaucher Disease
Learning Objective
After participating in the activity, learners should be better able to:
- Develop patient-focused management strategies for individuals diagnosed with Gaucher disease
The activities in this curriculum were approved for AMA PRA Category 1 Credit™.
Release date: 02/28/19
Expiration date: 02/28/20
Estimated time to complete: 0.25 hours each module
Activity Description
Although making a proper diagnosis can sometimes be a challenge even for common illnesses, in cases of patients who present with a rare disease such as Gaucher disease, properly diagnosing the disorder is especially challenging. Gaucher disease specialists often come across individuals who have lived with symptomatic Gaucher disease for years—into middle age or beyond—at which point treatment is much less effective. Although these individuals can gain some benefit from treatment, irreversible damage has often already occurred. Early consideration of Gaucher disease in the differential diagnosis of non-Gaucher disease specialists could allow individuals to avoid this outcome and gain maximal quality of life with effective therapy.
The modules of the digital curriculum below focus on the challenges of making a diagnosis of Gaucher disease, and how to co-manage these patients with the Gaucher disease expert once diagnosed.
Activity Faculty
Neal Weinreb, MD, FACP
Regional Coordinator and Chair of the International Collaborative Gaucher Group
University of Miami UHealth Sylvester Cancer Center Coral Springs
Coral Springs, FL
